Compare Boston Scientific Corporation (BSX) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Otis Worldwide Corp — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Otis Worldwide Corp trades at $72.54 (market cap $27.84B). The key difference: Boston Scientific Corporation is far larger — about 2.4× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays a 2.34% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | OTIS | |
|---|---|---|
Market Cap | $66.37B | $27.84B |
Sector | Health | Industrials |
52-Week High | $108.14 | $101.07 |
52-Week Low | $42.63 | $69.34 |
Enterprise Value | $75.94B | $35.23B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Otis Worldwide trades at $73.42, up 0.45% today, with a bullish technical signal from moving averages but mixed quarterly earnings. The company maintains stable revenue near $14.4B (2025) and a net margin of 10.11%, supported by service growth and modernization initiatives like recent upgrades at Christ the Redeemer in Brazil. Cash flow from operations remains strong at $1.6B, though net cash flow turned negative in 2025 due to financing activities.
The stock offers 24% upside to the consensus price target of $91.00, with analysts divided (38% Buy, 54% Hold). Risks include debt levels (75.54% debt-to-asset ratio) and margin pressure from tariffs, but dividend growth (5% increase to $0.44) and buybacks provide shareholder value. Near-term performance hinges on Q2 2026 earnings due July 22, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
